

Observed Disparities in Emergency Department-Initiated Buprenorphine Across Five Health Care Systems



Wesley C. Holland; Fangyong Li, MPH, MS; Bidisha Nath, MBBS, MPH; Molly M. Jeffery, PhD; Maria Stevens, MPH; Edward R. Melnick, MD, MHS; James D. Dziura, PhD; Rachel Skains, MD, MSPH; Gail D'Onofrio, MD, MS; William E. Soares III, MD MS

Disclosures

This work is supported by

- National Institutes of Health (NIH) Health Care Systems Research Collaboratory
- NIH Common Fund
- Office of Strategic Coordination within the Office of the NIH Director
- National Institute on Drug Abuse (NIDA)

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Authors report no other relevant conflicts of interest

Background




Aims

1. *Characterize racial and ethnic differences in the receipt of BUP*
2. *Explore racial and ethnic differences in ED Buprenorphine administration by provider and hospital level variables.*



Data Source



Don't give buprenorphine if patient is intoxicated or has taken methadone within 72 hours

- Data obtained from the EMBED (**EM**ergency department-initiated **BuprenorphinE** for opioid use **D**isorder) trial



EMBED:
PRAGMATIC TRIAL OF USER-CENTERED CLINICAL DECISION
SUPPORT TO IMPLEMENT EMERGENCY DEPARTMENT-INITIATED
BUPRENORPHINE FOR OPIOID USE DISORDER

Methods

Race

- White or Caucasian
- Black or African American
- Asian
- American Indian or Alaska Native
- Native Hawaiian or Pacific Islander
- Other



Ethnicity

- Hispanic
- Non-Hispanic



Four Analysis Groups

- Hispanic
- Non-Hispanic Black
- Non-Hispanic White
- Other

Methods

- **Type of Study:** Secondary analysis of EMBED data
- **Primary Outcome:** Proportion of patients who received BUP on index ED visit for OUD
 - Buprenorphine administered in ED or given as a prescription
- **Secondary Outcomes:**
 - Community vs academic ED
- **Analysis:** Generalized linear mixed models with repeated effects (GLIMMIX) clustered for provider and site

Results

Table 1. Patient Characteristics

| | Hispanic (N = 701) | Non-Hispanic Black (N = 801) | Non-Hispanic White (N = 3154) |
|-------------------|-----------------------|------------------------------------|-------------------------------------|
| Age (mean, SD) | 39.0 (12.3) | 43.0 (14.4) | 38.5 (12.8) |
| Gender (N, %) | | | |
| <i>Female</i> | 172 (24.5%) | 247 (30.8%) | 1184 (37.5%) |
| <i>Male</i> | 529 (75.5%) | 554 (69.2%) | 1970 (62.5%) |
| Insurance (N, %) | | | |
| <i>Medicaid</i> | 312 (44.5%) | 348 (43.4%) | 1073 (34.0%) |
| <i>Medicare</i> | 59 (8.4%) | 126 (15.7%) | 368 (11.7%) |
| <i>Private</i> | 232 (33.1%) | 102 (12.7%) | 732 (23.2%) |
| <i>Self-Pay</i> | 79 (11.3%) | 197 (24.6%) | 833 (26.4%) |
| Diagnosis (N, %) | | | |
| <i>Overdose</i> | 317 (45.2%) | 273 (34.1%) | 1046 (33.2%) |
| <i>Withdrawal</i> | 109 (15.5%) | 102 (12.7%) | 565 (17.9%) |

Results

Table 1. Patient Characteristics

| | Hispanic (N = 701) | Non-Hispanic Black (N = 801) | Non-Hispanic White (N = 3154) |
|-------------------|-----------------------|------------------------------------|-------------------------------------|
| Age (mean, SD) | 39.0 (12.3) | 43.0 (14.4) | 38.5 (12.8) |
| Gender (N, %) | | | |
| <i>Female</i> | 172 (24.5%) | 247 (30.8%) | 1184 (37.5%) |
| <i>Male</i> | 529 (75.5%) | 554 (69.2%) | 1970 (62.5%) |
| Insurance (N, %) | | | |
| <i>Medicaid</i> | 312 (44.5%) | 348 (43.4%) | 1073 (34.0%) |
| <i>Medicare</i> | 59 (8.4%) | 126 (15.7%) | 368 (11.7%) |
| <i>Private</i> | 232 (33.1%) | 102 (12.7%) | 732 (23.2%) |
| <i>Self-Pay</i> | 79 (11.3%) | 197 (24.6%) | 833 (26.4%) |
| Diagnosis (N, %) | | | |
| <i>Overdose</i> | 317 (45.2%) | 273 (34.1%) | 1046 (33.2%) |
| <i>Withdrawal</i> | 109 (15.5%) | 102 (12.7%) | 565 (17.9%) |

Results

Table 1. Patient Characteristics

| | Hispanic (N = 701) | Non-Hispanic Black (N = 801) | Non-Hispanic White (N = 3154) |
|-------------------|-----------------------|------------------------------------|-------------------------------------|
| Age (mean, SD) | 39.0 (12.3) | 43.0 (14.4) | 38.5 (12.8) |
| Gender (N, %) | | | |
| <i>Female</i> | 172 (24.5%) | 247 (30.8%) | 1184 (37.5%) |
| <i>Male</i> | 529 (75.5%) | 554 (69.2%) | 1970 (62.5%) |
| Insurance (N, %) | | | |
| <i>Medicaid</i> | 312 (44.5%) | 348 (43.4%) | 1073 (34.0%) |
| <i>Medicare</i> | 59 (8.4%) | 126 (15.7%) | 368 (11.7%) |
| <i>Private</i> | 232 (33.1%) | 102 (12.7%) | 732 (23.2%) |
| <i>Self-Pay</i> | 79 (11.3%) | 197 (24.6%) | 833 (26.4%) |
| Diagnosis (N, %) | | | |
| <i>Overdose</i> | 317 (45.2%) | 273 (34.1%) | 1046 (33.2%) |
| <i>Withdrawal</i> | 109 (15.5%) | 102 (12.7%) | 565 (17.9%) |

Results

Table 2. ED Provider and Hospital Characteristics

| | Hispanic (N = 701) | Non-Hispanic Black (N = 801) | Non-Hispanic White (N = 3154) |
|-----------------------------------|------------------------------|--|---|
| Provider Gender (N, %) | | | |
| Female | 260 (37.1%) | 213 (26.6%) | 831 (26.3%) |
| Male | 430 (61.3%) | 559 (69.8%) | 2135 (67.7%) |
| Provider Age (N, %) | | | |
| 35-44 | 314 (45.5%) | 344 (44.6%) | 1164 (39.2%) |
| 45+ | 269 (39.0%) | 299 (38.7%) | 1227 (41.4%) |
| <35 | 107 (15.5%) | 129 (16.7%) | 575 (19.4%) |
| Provider X-Waivered (N, %) | 441 (62.9%) | 488 (60.9%) | 1786 (56.6%) |
| Community ED | 357 (50.9%) | 441 (55.1%) | 1890 (59.9%) |
| Urban ED | 583 (83.2%) | 657 (82%) | 2218 (70.3%) |


Results

Table 2. ED Provider and Hospital Characteristics

| | Hispanic (N = 701) | Non-Hispanic Black (N = 801) | Non-Hispanic White (N = 3154) |
|-----------------------------------|-----------------------|---------------------------------|----------------------------------|
| Provider Gender (N, %) | | | |
| Female | 260 (37.1%) | 213 (26.6%) | 831 (26.3%) |
| Male | 430 (61.3%) | 559 (69.8%) | 2135 (67.7%) |
| Provider Age (N, %) | | | |
| 35-44 | 314 (45.5%) | 344 (44.6%) | 1164 (39.2%) |
| 45+ | 269 (39.0%) | 299 (38.7%) | 1227 (41.4%) |
| <35 | 107 (15.5%) | 129 (16.7%) | 575 (19.4%) |
| Provider X-Waivered (N, %) | 441 (62.9%) | 488 (60.9%) | 1786 (56.6%) |
| Community ED | 357 (50.9%) | 441 (55.1%) | 1890 (59.9%) |
| Urban ED | 582 (83.2%) | 657 (82.0%) | 2218 (70.3%) |

Results

Receipt of Buprenorphine by Race / Ethnicity



Results

Table 3. GLIMMIX model with cluster effects for site and provider evaluating the odds of ED buprenorphine receipt by race and ethnicity

| | Unadjusted OR (95% CI) | P value | Adjusted OR (95% CI) | P value |
|---|-----------------------------------|----------------|---------------------------------|----------------|
| Non-Hispanic White vs Non-Hispanic Black | 1.57 (1.18, 2.09) | 0.002 | 1.42 (1.06, 1.9) | 0.02 |
| Hispanic vs Non- Hispanic Black | 1.88 (1.28, 2.77) | 0.0012 | 1.78 (1.21, 2.62) | 0.004 |
| Hispanic vs Non- Hispanic White | 1.20 (0.89, 1.62) | 0.23 | 1.25 (0.93, 1.69) | 0.14 |

Adjusted for patient age, gender, insurance, provider X-Waiver status and type of ED

Results



- We found no difference in racial disparity in receipt of buprenorphine between community and academic sites. (interaction $p=0.94$)

Results

Table 4. GLIMMIX model with cluster effects for site and provider evaluating the odds of ED buprenorphine receipt by race.

| | Adjusted* OR (95% CI) | P value |
|-------------------|----------------------------------|----------------|
| White vs. Black** | 1.57 (1.19, 2.08) | 0.002 |

*Adjusted for patient age, gender, insurance, provider X-Waiver status and type of ED

**Insufficient numbers of patients categorized in other racial groups for analysis (Asian=15, American Indian or Alaska Native=13, Native Hawaiian or Pacific Islander=7)

Limitations



- Generalizability
- Variable and inconsistent recording of race/ethnicity data
- Missing race and/or ethnicity data

Conclusions

- Non-Hispanic Black patients were significantly less likely to receive BUP in ED.
- Add one more bullet point, maybe academic vs community secondary outcome



Questions?

- And thank you to all of the co-authors and collaborators!
- Contact Info: Wesley Holland
Wesley.holland@yale.edu

